Medicalgorithmics S.A. is a Health Care company. Its directors and officers file their transactions with KNF. Over the twelve months to 24 October 2026, 5 filings were filed, from 2 insiders.
There is no open-market purchase to report; the filings show 2 sales worth €26.4M by 1 insider. Biggest ticket of the year: €15.9M, sold and made public on 19 January 2026.
Across the 216 companies tracked on its exchange, the median is 4 filings; at 5 filings, this issuer sits above that mark. Our records for Medicalgorithmics S.A. go back to 2026, with no purchases and 2 sales on the open market in total.
Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. This summary is built from KNF disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
5 of 5 declarations
Medicalgorithmics S.A. is a company focused on developing technological solutions for the healthcare sector. It is listed on the XWAR market.
Purchases our model currently ranks for the recommendations list.
All recommendations